Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Cut to $19.00 by Analysts at The Goldman Sachs Group
Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price target cut by The Goldman Sachs Group from $22.00 to $19.00 in a report issued on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other research analysts have also recently commented on the company. Chardan Capital lowered their […]
Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price target cut by The Goldman Sachs Group from $22.00 to $19.00 in a report issued on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other research analysts have also recently commented on the company. Chardan Capital lowered their […]
